Peraud A - Search Results

1

Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.

Ständer M, Peraud A, Leroch B, Kreth FW. Ständer M, et al. Among authors: peraud a. Cancer. 2004 Sep 1;101(5):1028-35. doi: 10.1002/cncr.20432. Cancer. 2004. PMID: 15329912 Free article.

2

Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.

Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Peraud A, et al. Clin Cancer Res. 2002 May;8(5):1117-24. Clin Cancer Res. 2002. PMID: 12006527

3

[Pilocytic astrocytoma in childhood].

Goetz C, Peraud A, Kreth FW, Tonn JC. Goetz C, et al. Among authors: peraud a. MMW Fortschr Med. 2004 Apr 1;146(14):24-5. MMW Fortschr Med. 2004. PMID: 15344746 Review. German. No abstract available.

4

[Individualized treatment strategies in adults with supratentorial WHO grade II gliomas].

Kreth FW, Peraud A, Tonn JC. Kreth FW, et al. Among authors: peraud a. MMW Fortschr Med. 2004 Apr 1;146(14):26-8. MMW Fortschr Med. 2004. PMID: 15344747 Review. German. No abstract available.

5

Interstitial iodine-125 radiosurgery alone or in combination with microsurgery for pediatric patients with eloquently located low-grade glioma: a pilot study.

Peraud A, Goetz C, Siefert A, Tonn JC, Kreth FW. Peraud A, et al. Childs Nerv Syst. 2007 Jan;23(1):39-46. doi: 10.1007/s00381-006-0203-7. Epub 2006 Sep 14. Childs Nerv Syst. 2007. PMID: 16972111 Clinical Trial.

6

Early treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery.

Kunz M, Nachbichler SB, Ertl L, Fesl G, Egensperger R, Niyazi M, Schmid I, Tonn JC, Peraud A, Kreth FW. Kunz M, et al. Among authors: peraud a. Cancer Med. 2016 Mar;5(3):442-53. doi: 10.1002/cam4.605. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26714663 Free PMC article.

7

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW. Thon N, et al. Among authors: peraud a. Cancer. 2012 Jan 15;118(2):452-60. doi: 10.1002/cncr.26298. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717448 Free article.

8

Clinical outcome of supratentorial astrocytoma WHO grade II.

Peraud A, Ansari H, Bise K, Reulen HJ. Peraud A, et al. Acta Neurochir (Wien). 1998;140(12):1213-22. doi: 10.1007/s007010050241. Acta Neurochir (Wien). 1998. PMID: 9932120

9

Compare and contrast: pediatric cancer versus adult malignancies.

Kattner P, Strobel H, Khoshnevis N, Grunert M, Bartholomae S, Pruss M, Fitzel R, Halatsch ME, Schilberg K, Siegelin MD, Peraud A, Karpel-Massler G, Westhoff MA, Debatin KM. Kattner P, et al. Among authors: peraud a. Cancer Metastasis Rev. 2019 Dec;38(4):673-682. doi: 10.1007/s10555-019-09836-y. Cancer Metastasis Rev. 2019. PMID: 31832830 Review.

10

Molecular genetic investigations in the CCM1 gene in sporadic cerebral cavernomas.

Reich P, Winkler J, Straube A, Steiger HJ, Peraud A. Reich P, et al. Among authors: peraud a. Neurology. 2003 Apr 8;60(7):1135-8. doi: 10.1212/01.wnl.0000055470.62265.44. Neurology. 2003. PMID: 12682320

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters